Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study

Aims To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co‐transporter 2 ( SGLT2 ) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion ( UGE ), renal threshold for glucose excretion ( RT G ) and postprandial plasma glucose ( PPG ) excursion in healthy participants in a randomized, double‐blind, two‐period crossover study. Methods In each treatment period, participants (n = 54) received...